Liver enzyme variability and risk of heart disease and mortality: A nationwide population‐based study
Liver International Mar 24, 2020
Cho EJ, et al. - In this nationwide population‐based study involving 6,496,271 individuals partaking in ≥ 3 health examinations within the previous 5 years including the index year (2009‐2010), researchers intended to determine if there is a connection between liver enzymes [ie, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and γ‐glutamyltransferase (GGT)] variability and the risk of mortality and cardiovascular outcomes in general population. Using variability independent of the mean, variability was measured. Findings revealed that there were 106,413 deaths (1.6%), 53,385 myocardial infarctions (MI, 0.8%), 65,143 atrial fibrillations (AF, 1.0%) and 50,139 congestive heart failures (CHF, 0.7%) during a median follow‐up of 6 years. High variability in AST, ALT and GGT was linked to a higher risk for all‐cause mortality, MI, AF and CHF. An independent predictor of all‐cause mortality and cardiovascular events was higher visit‐to‐visit variability of liver enzymes.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries